Companies at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

268 companies are at ASHG 2026 — 330 presentations on the program and 163 with a booth in the exhibit hall. Most represented: Illumina (19 on the program), LabCorp (19 on the program), Ambry Genetics (11 on the program). 168 of them have their own page in this guide. As of Sep 25, 2026.

All 1,062 organizations at ASHG 2026 →

Scientific focus
Top represented
Showing 1–2 of 268 organizations
OrganizationASHG 2026 Attendance
Illumina
San Diego, California
1 Senior Manager · 1 Vice President and Global Head of Advanced Science · 1 Sr Director, R&D · 1 Sr Director, Scientific Research-Advanced Platforms · 1 other presenter
Public company~8,600 people
Illumina sells DNA sequencing and array-based technologies. It serves research, clinical, and applied-market customers.
Illumina's Billion Cell Atlas alliance added AI-native drug developer Formation Bio and other members, widening its AI-biopharma customer reach.
›
Illumina's Billion Cell Atlas alliance added AI-native drug developer Formation Bio and other members, widening its AI-biopharma customer reach.
2026-07 · source
Illumina appointed Sullivan and Coletti to its executive leadership team, adding experienced decision-makers you may now be selling to.
2026-07 · source
Illumina launched StrataMap Spatial, a new whole-transcriptome spatial platform, giving customers an in-house option instead of buying elsewhere.
2026-06 · source
Source: company newsroom
Q2 2026 revenue $1.16B, up 9.5%
›
FY2026 guidance raised to $4.60-$4.64 billion, signaling steady growth and budget for sequencing purchases. · 2026-07-30
“Revenue of $1.16 billion for Q2 2026, up 9.5% from Q2 2025. For fiscal year 2026, we now expect total revenue of $4.60-$4.64 billion.”
Source: results release
Currently hiring
›
Source: careers page
Booth
Exhibiting at Booth 701
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Session
Tue Oct 20
10:00 am
Strategies for Communicating Your Science
Plenary
Tue Oct 20
5:00 pm
Automated interpretation of rare disease genomes with deep graph attention
Collaborators: University of Oxford, Queen Mary University of London +1 more
Artificial intelligenceBioinformaticsVariant interpretationGenotype-phenotype correlations
Poster
Wed Oct 21
2:30 pm
Proximity-informed structural variant detection with Illumina TruPath Genome
Copy number/structural variationGenomic structureSequencing technology
Poster
Wed Oct 21
2:30 pm
A unified deep learning framework for quantitative splicing and transcript prediction
Collaborators: University of Oxford
Alternative splicingArtificial intelligenceDeep learningGenomics
Poster
Wed Oct 21
2:30 pm
Poster
Thu Oct 22
4:15 pm
Adapting Illumina Single Cell 3’ RNA Kit for 3′ Single Cell V(D)J Enrichment: Enabling Paired TCR α/β Recovery on the MiSeq™ i100 Plus
Alternative splicingSingle-cellImmune systemTranscriptome
Poster
Thu Oct 22
4:15 pm
Reliable detection of uniparental disomy from trio sequencing data using chromosome scale inheritance patterns
BioinformaticsClinical geneticsCopy number/structural variationChromosomal abnormalities
Poster
Fri Oct 23
2:30 pm
A streamlined method for simultaneous, high accurate methylation profiling and whole genome sequencing in FFPE sample types
MethylationGenomicsExome/genome sequencingEpigenetics
Poster
Fri Oct 23
2:30 pm
Poster
Fri Oct 23
2:30 pm
Enabling flexible small-scale Illumina Spatial Technology workflow for benchtop sequencing platforms
Multi-omicsNon-coding RNARNASpatial transcriptomics
Poster
Fri Oct 23
2:30 pm
Resolving challenging genes for nonsyndromic sensorineural hearing loss using on flowcell proximity sequencing
Collaborators: Boston Children's Hospital
Sequencing technologyVariant callingCopy number/structural variationLaboratory genetics and genomics
Poster
Fri Oct 23
2:30 pm
Poster
Fri Oct 23
2:30 pm
Advancing Whole-Exome Sequencing Through Optimized Coverage and Enrichment Performance
Exome/genome sequencingLaboratory genetics and genomicsGenetic testingGenomics
Poster
Fri Oct 23
2:30 pm
Targeted Profiling of CYP2D6, CYP2B6 and CYP21A2 in an Integrated Exome-Based NGS Workflow
Clinical testingComputational toolsCopy number/structural variationExome/genome sequencing
Poster
Fri Oct 23
2:30 pm
Poster
Fri Oct 23
2:30 pm
Inter-individual multiomics improves subtype resolution and risk stratification in cardiovascular disease
Collaborators: Henry Ford Health
Multi-omicsCardiovascular systemGene regulationMachine learning
LabCorp
Burlington, Vermont
1 Lab Director · 1 Senior Applied Research Scientist in Oncology · 1 Data scientist · 1 Statistical Geneticist · 4 other presenters
Public company~71,000 people
Labcorp is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions.
Labcorp is collaborating with OHSU on a study evaluating blood-based MRD testing for earlier detection of bladder-cancer recurrence.
›
Labcorp is collaborating with OHSU on a study evaluating blood-based MRD testing for earlier detection of bladder-cancer recurrence.
2026-09 · source
Labcorp acquired MLM Medical Labs, a global central and specialty laboratory provider, expanding its central-lab capacity for trial sponsors.
2026-09 · source
Labcorp enhanced its Global Trial Connect platform, upgrading the digital tools it offers clinical-trial sponsors and data teams.
2026-08 · source
Source: company newsroom
Q2 2026 revenue $3.73B, up 5.8%
›
FY2026 revenue-growth guidance of 5.4%-6.3% points to continued expansion of its testing and trial services. · 2026-07-30
“Revenue: $3.73 billion vs. $3.53 billion, up 5.8%; Annual revenue growth guidance of 5.4% to 6.3%.”
Source: results release
Booth
Exhibiting at Booth 1024
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Session
Wed Oct 21
1:30 pm
Poster
Wed Oct 21
2:30 pm
Preoperative Lynch syndrome diagnosis and surgical outcomes in colorectal cancer: Evaluating resection extent, post-operative complications, and rates of metachronous and other cancers
Collaborators: Duke Medical Center, Memorial Sloan Kettering Cancer Center
CancerGenetic testingPublic healthCancer syndromes
Poster
Wed Oct 21
2:30 pm
Poster
Wed Oct 21
2:30 pm
Poster
Wed Oct 21
2:30 pm
From global calibration to gene-aware evidence: calibrating pathogenicity predictions for real-world variant interpretation
Artificial intelligenceVariant interpretationMethodologyGenetic testing
Talk
Thu Oct 22
2:15 pm
Surveying the structural variant landscape in genetic testing: Prevalence and diagnostic yield in a clinical cohort of 1.8 million individuals
Clinical geneticsCopy number/structural variationDiagnosticsGenetic testing
Poster
Thu Oct 22
4:15 pm
★ Reviewers’ Choice
The impact of an iterative points-based framework on variant classification outcomes for neurodevelopmental disorders.
Artificial intelligenceVariant interpretationNeurodevelopmentalClinical testing
Poster
Thu Oct 22
4:15 pm
Applying Single Cell Transcriptomics and Machine Learning to Classify SCN1A Variants According to Disease Mechanism
Laboratory genetics and genomicsGenomicsMachine learningGenetic variation
Poster
Thu Oct 22
4:15 pm
A machine learning framework for accurate SMN1 copy number determination from short-read next-generation sequencing data
BioinformaticsCopy number/structural variationGenomicsMachine learning
Poster
Thu Oct 22
4:15 pm
Biochemical data and genetic testing: combining datasets to help classify variants
Laboratory genetics and genomicsVariant interpretationPhenotypeMetabolic disorder
Poster
Fri Oct 23
2:30 pm
Assessment of Structural and Copy Number Variants in Constitutional Samples Using Electronic Genome Mapping
AneuploidyChromosomal abnormalitiesClinical testingCopy number/structural variation
Poster
Fri Oct 23
2:30 pm
Validating gain- and loss-of-function multiplexed assay of variant effect (MAVE) predictions using linked genetic testing and biochemical datasets: a CASR case study
Variant interpretationGenotype-phenotype correlationsMendelian disorderRare variants
Poster
Fri Oct 23
2:30 pm
Evidence supporting RPS20 as a colorectal cancer susceptibility gene from a case-control study
Collaborators: University of Pittsburgh
CancerCancer syndromesGenetic epidemiologyGenetic testing
Poster
Fri Oct 23
2:30 pm
A conversational AI agent for multi-domain clinicogenomic research analytics with layered human-in-the-loop verification
Artificial intelligenceComputational toolsDatabasesGenotype-phenotype correlations
Poster
Fri Oct 23
2:30 pm
Single-cell transcriptomic variant effect mapping of clinically relevant MSH3 variants
Machine learningMassively parallel sequencingVariant interpretation

Explore the full ASHG 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Montréal. Leave your work email and we’ll be in touch.

Privacy

Download the full ASHG 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from companies

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Browse ASHG 2026 by

Exhibit hall

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction